Delving into the Latest Updates on Chlorothiazide with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

6-Chloro-1,1-dioxo-1,2-dihydro-1lambda*6*-benzo[1,2,4]thiadiazine-7-sulfonic acid amide, 6-chloro-7-sulfamoyl-2H-1,2,4-benzothiadiazine 1,1-dioxide, CHLOROTHIAZIDE SODIUM

+ [6]

Target

NCC

Action

inhibitors

Mechanism

NCC inhibitors(Thiazide-sensitive sodium-chloride cotransporter inhibitors)

Therapeutic Areas

Cardiovascular DiseasesDigestive System DisordersUrogenital Diseases+ [1]

Active Indication

EdemaGlomerulonephritisHeart Failure+ [5]

Inactive Indication-

Originator Organization

Novartis Pharma AG

Active Organization

Salix Pharmaceuticals, Inc.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

United States (06 Oct 1961),

EdemaGlomerulonephritisHeart Failure+ [5]

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC7H6ClN3O4S2

InChIKeyJBMKAUGHUNFTOL-UHFFFAOYSA-N

CAS Registry58-94-6

Broad Objectives: To determine the comparative efficacy of commonly employed strategies to overcome loop diuretic resistance when added to concomitant loop diuretics in hospitalized decompensated heart failure patients with hypervolemia
Specific Aims:
Compare the 48-hour weight change of either intravenous chlorothiazide or oral tolvaptan compared to standard-of-care oral metolazone when combined with standardized loop diuretic dosing for diuretic resistance in decompensated heart failure
Compare the adverse effects of electrolyte depletion and renal function changes between intravenous chlorothiazide or oral tolvaptan compared to standard-of-care oral metolazone when combined with standardized loop diuretic dosing for diuretic resistance in acute heart failure
Pharmacoeconomic analysis of the direct costs of intravenous chlorothiazide or oral tolvaptan compared to standard-of-care oral metolazone when combined with standardized loop diuretic dosing for diuretic resistance in acute heart failure
The investigators will conduct a dual center, randomized, double-blind, double-dummy, parallel design trial comparing: oral metolazone, intravenous chlorothiazide, or oral tolvaptan, in combination with loop diuretics in 60 patients hospitalized for hypervolemic decompensated heart failure and displaying loop diuretic resistance.

Start Date01 Feb 2016

Sponsor / Collaborator

Vanderbilt University

NCT05840536

/ WithdrawnPhase 4

Efficacy and Tolerability of Combination Intravenous Diuretic Therapy Versus Intravenous Loop Diuretic Therapy Alone for the Treatment of Acute Decompensated Heart Failure

Patients with heart failure are often admitted to the hospital because they have accumulated excessive amounts of fluid, they become short of breath and congested with fluid. Removing the excess fluid is necessary to improve the patients symptoms and reduce the risk of being re-admitted to the hospital. Diuretics ("water pills") are often given through an IV to accelerate the fluid removal. Furosemide is commonly used for fluid removal, however some patients do not respond well to the medication. There are other diuretics available that can work in conjunction with furosemide and increase the rate of fluid removal. The other "water pills" have slightly different mechanisms of action in the body compared to furosemide and when combined they may increase fluid removal.
The investigators hypothesize that adding chlorothiazide to furosemide will result in quicker and more effective fluid removal in heart failure patients.

Start Date01 May 2014

Sponsor / Collaborator

Ochsner Home Medical Equipment, L.L.C

100 Clinical Results associated with Chlorothiazide

Login to view more data

100 Translational Medicine associated with Chlorothiazide

Login to view more data

100 Patents (Medical) associated with Chlorothiazide

Login to view more data

3,669

Literatures (Medical) associated with Chlorothiazide

01 Mar 2025·Journal of Perinatology

Association of furosemide versus chlorothiazide exposures with serum sodium, potassium, and chloride among infants with bronchopulmonary dysplasia

Article

Author: Lorch, Scott A ; Napolitano, Natalie ; Bamat, Nicolas A ; Nelin, Timothy D. ; Morris, Heidi ; Bustin, Anna ; Gibbs, Kathleen ; Alexiou, Stamatia ; Bamat, Nicolas A. ; DeMauro, Sara B. ; Nelin, Timothy D ; DeMauro, Sara B ; Huber, Matthew ; Lorch, Scott A. ; Jensen, Erik A. ; Jensen, Erik A

AbstractObjectivesTo examine the association of novel furosemide versus thiazide diuretic exposure with changes in serum sodium, potassium, and chloride levels among infants with grade 2/3 bronchopulmonary dysplasia (BPD).Study DesignRetrospective cohort study of infants admitted to a level IV neonatal intensive care unit (NICU) with grade 2/3 BPD. We measured within-subject change in serum sodium, potassium, and chloride before and after diuretic initiation using multivariable regression to adjust for differences in dosing and clinical covariates.ResultsWe identified 94 infants contributing 137 novel diuretic exposures. No significant difference was noted in the association between chlorothiazide versus furosemide and serum sodium, potassium, or chloride change in multivariable modeling.ConclusionsChanges in serum electrolytes were similar for chlorothiazide and furosemide, questioning the perception that chlorothiazide leads to less electrolyte derangement among preterm infants with grade 2/3 BPD.

01 Mar 2025·Biological Psychiatry

The NKCC1 Inhibitor Bumetanide Restores Cortical Feedforward Inhibition and Lessens Sensory Hypersensitivity in Early Postnatal Fragile X Mice

Article

Author: Wu, Michelle ; Heuvelmans, Anouk ; Dobler, Zoë ; Contractor, Anis ; Nomura, Toshihiro ; Kourdougli, Nazim ; Portera-Cailliau, Carlos

BACKGROUNDExaggerated responses to sensory stimuli, a hallmark of fragile X syndrome, contribute to anxiety and learning challenges. Sensory hypersensitivity is recapitulated in the Fmr1 knockout (KO) mouse model of fragile X syndrome. Recent studies in Fmr1 KO mice have demonstrated differences in the activity of cortical interneurons and a delayed switch in the polarity of GABA (gamma-aminobutyric acid) signaling during development. Previously, we reported that blocking the chloride transporter NKCC1 with the diuretic bumetanide could rescue synaptic circuit phenotypes in the primary somatosensory cortex (S1) of Fmr1 KO mice. However, it remains unknown whether bumetanide can rescue earlier circuit phenotypes or sensory hypersensitivity in Fmr1 KO mice.METHODSWe used acute and chronic systemic administration of bumetanide in Fmr1 KO mice and performed in vivo 2-photon calcium imaging to record neuronal activity, while tracking mouse behavior with high-resolution videos.RESULTSWe demonstrated that layer 2/3 pyramidal neurons in the S1 of Fmr1 KO mice showed a higher frequency of synchronous events on postnatal day 6 than wild-type controls. This was reversed by acute administration of bumetanide. Furthermore, chronic bumetanide treatment (postnatal days 5-14) restored S1 circuit differences in Fmr1 KO mice, including reduced neuronal adaptation to repetitive whisker stimulation, and ameliorated tactile defensiveness. Bumetanide treatment also rectified the reduced feedforward inhibition of layer 2/3 neurons in the S1 and boosted the circuit participation of parvalbumin interneurons.CONCLUSIONSThis further supports the notion that synaptic, circuit, and sensory behavioral phenotypes in Fmr1 KO can be mitigated by inhibitors of NKCC1, such as the Food and Drug Administration-approved diuretic bumetanide.

01 Feb 2025·Analytical and Bioanalytical Chemistry

LC-HRMS screening procedure for the detection of 11 different classes of prohibited substances in dried urine spots for doping control purposes

Article

Author: Tsivou, Maria ; Pizzolato, Francesca ; Honesová, Lenka ; Gmeiner, Günter ; Mazzarino, Monica ; Van Eenoo, Peter

Dried urine spots have recently been proposed as an alternative matrix in the anti-doping field. Drying urine may open the opportunity to limit microbial and thermal degradation of the prohibited substances during transportation to the anti-doping laboratories without the need for refrigeration or freezing. In this study, a multi-targeted initial testing procedure was developed for the determination of 237 prohibited drugs/metabolites from 11 different classes in dried urine spots. The comparability between two different microsampling techniques (i.e., Whatman^® FTA DMPK-C cards and Mitra^® tips) was evaluated. The developed method was then used to evaluate the stability of the target compounds in urine for 7 days under different environmental conditions to simulate the transportation of the urine samples from the collection sites to anti-doping laboratories. Sample preparation consists of (i) extraction of the analytes from the collection device using a mixture of acetonitrile/methanol (1/1) for 30 min at 40 °C, (ii) enzymatic hydrolysis, and (iii) sample concentration by solid-phase extraction. Analysis was performed using liquid chromatography coupled to high-resolution mass spectrometry. The entire workflow was validated in terms of specificity (analytes were distinguishable from the matrix interferences), sensitivity (only with the Mitra^® tips the limits of detection comply with the World Anti-Doping Agency's requirements for the majority of the target compounds), carry-over (no signals in the negative urine injected after the positive urine), matrix effect (16-28% for Mitra^® tips and 22-35% for DMPK-C cards), and extraction yield (Mitra^® tips: 51-88%; DMPK-C cards: 40-76%). As proof of concept, authentic urine samples were analyzed: results obtained in dried urine were compared with those of fluid urine, providing good agreement. Stability studies showed that the target compounds were stable for the whole duration of the study (7 days) at -20 and 4 °C in both fluid and dried urine. At 50 °C or at 20-25 °C, several thiazide-based compounds were completely degraded to their degradation product in the first 24 h or after 3-4 days in fluid urine, whereas in dried urine the compounds were detectable for the entire duration of the study.

1

News (Medical) associated with Chlorothiazide

21 Oct 2009

·www.biospace.com

APP Pharmaceuticals Receives Approval for the First Generic Chlorothiazide Sodium for Injection, USP

SCHAUMBURG, Ill.--(BUSINESS WIRE)--APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., (NASDAQ:APCVZ) announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market Chlorothiazide Sodium for Injection, USP. APP expects to launch Chlorothiazide Sodium for Injection, USP in the fourth quarter of 2009.

100 Deals associated with Chlorothiazide

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00519	Chlorothiazide	C03AA04	DB00880

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Edema	United States	Salix Pharmaceuticals, Inc.	06 Oct 1961
Glomerulonephritis	United States	Salix Pharmaceuticals, Inc.	06 Oct 1961
Heart Failure	United States	Salix Pharmaceuticals, Inc.	06 Oct 1961
Hypertension	United States	Salix Pharmaceuticals, Inc.	06 Oct 1961
Kidney Failure, Chronic	United States	Salix Pharmaceuticals, Inc.	06 Oct 1961
Liver Cirrhosis	United States	Salix Pharmaceuticals, Inc.	06 Oct 1961
Nephrotic Syndrome	United States	Salix Pharmaceuticals, Inc.	06 Oct 1961
Renal Insufficiency	United States	Salix Pharmaceuticals, Inc.	06 Oct 1961

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02606253 (3T, CTgov)	Phase 4	Heart Failure	60	Metolazone (Metolazone)	yznbdhxbrq(vmevevisjd) = wcqqjrrguc ptpwmwsswz (ziakzihvwc, mjvdqffdoi - qnswdnublf) View more	-	08 Nov 2019
				Chlorothiazide (Chlorothiazide)	yznbdhxbrq(vmevevisjd) = crqspyzgsj ptpwmwsswz (ziakzihvwc, qvfddzkuwz - nrkclojcij) View more